Milestone Pharmaceuticals Inc.
MIST
Positions held
Your positionsMIST isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | $88.66M | Enterprise value | $71.57M | Trailing P/E | — | Forward P/E | -0.92 |
| PEG | — | Price / book | 5.52 | Beta | 1.01 | Dividend yield | 0.00% |
| Revenue growth | — | Earnings growth | — | Gross margin | 98.0% | Operating margin | -45.8% |
| Profit margin | 0.0% | ROE | -355.2% | ROA | -42.8% | Debt / equity | 7.79 |
| Current ratio | 8.13 | Free cash flow | -$41.69M | Analyst recommendation | none | Mean target | $5.86 |
| 52w high | $3.06 | 52w low | $0.71 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $0.6M | $0.2M | $1.5M | $0.0M | $0.0M | — |
| Op margin | -4585.0% | -9942.4% | -1116.2% | — | — | — |
| Net income | -$28.6M | -$26.1M | -$17.4M | -$11.9M | -$13.0M | — |
| Gross margin | 94.3% | 94.1% | — | — | — | — |
| Gross profit | $0.5M | $0.2M | — | — | $0.0M | $0.0M |
| Operating income | -$25.6M | -$23.7M | -$17.3M | -$11.8M | -$12.5M | — |
- Revenue +135% vs prior quarter ($0.6M vs $0.2M).
- Gross margin 94.3% (was 94.1% prior quarter).
- Operating margin expanded to -4585%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $1.5M | $0.0M | $1.0M | $5.0M | — |
| Op margin | -4019.4% | — | -6109.8% | -1192.8% | — |
| Net income | -$63.1M | -$41.5M | -$59.7M | -$58.4M | — |
| Gross margin | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$62.1M | -$42.1M | -$61.1M | -$59.6M | — |
Headlines — watch
• [WARN · fundamentals] Milestone Pharmaceuticals shares tumble after Q2 earnings miss
News
2026-09-02 · Milestone Pharmaceuticals to Present at Upcoming Investor Conferences
2026-08-21 · Milestone Pharmaceuticals shares rise as first patient enters Phase 3 AFib trial
2026-08-21 · Milestone Starts Phase 3 Trial of Nasal Spray for Atrial Fibrillation With Rapid Heart Rate
2026-08-20 · Cantor Fitzgerald Initiates Milestone Pharmaceuticals at Overweight With $3 Price Target
2026-08-13 · Milestone Pharmaceuticals Inc. Q2 2026 Earnings Call Summary
2026-08-12 · Milestone Pharmaceuticals Q2 Earnings Call Highlights
2026-08-12 · Milestone Pharmaceuticals (MIST) Reports Q2 Loss, Lags Revenue Estimates
2026-08-12 · Milestone Pharmaceuticals shares tumble after Q2 earnings miss
Price (daily)
Full chart · RSI · MACD · patterns